R&D | January 14, 2026
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Subscribe To Our Newsletter & Stay Updated
